Intracameral Gas SF6 (Sulfur Hexafluoride) Injection for Acute Hydrops in Keratoconus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2008 by HaEmek Medical Center, Israel.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00593190
First received: January 1, 2008
Last updated: January 11, 2008
Last verified: January 2008
  Purpose

Intracameral Gas SF6 (Sulfur Hexafluoride) Injection for Acute Hydrops in Keratoconus


Condition Intervention
Hydrops in Keratoconus
Drug: Gas SF6 (Sulfur Hexafluoride)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • Hydrops resulotion [ Time Frame: weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 10
Study Start Date: January 2008
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Gas SF6 (Sulfur Hexafluoride)
ONCE

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hydrops

Exclusion Criteria:

  • Age < 18 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00593190

Contacts
Contact: Boris Safianik, Dr 972-4-6494000

Locations
Israel
HaEmek Medical Center Recruiting
Afula, Israel
Principal Investigator: Boris Safianik, Dr         
Sponsors and Collaborators
HaEmek Medical Center, Israel
  More Information

No publications provided

Responsible Party: Dr. Boris Safianik, Ha'Emek Medical Center
ClinicalTrials.gov Identifier: NCT00593190     History of Changes
Other Study ID Numbers: 0097-07-EMC
Study First Received: January 1, 2008
Last Updated: January 11, 2008
Health Authority: Israel: Ethics Commission

Additional relevant MeSH terms:
Keratoconus
Edema
Corneal Diseases
Eye Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on September 18, 2014